As Covidien (NYSE:COV) closed its 4th recent acquisition, analysts speculated that there may be more deals on the near future.

The Mansfield, Mass.-based company may be looking to pick up some assets in hypertension treatment, or may keep its sights on additional acquisitions in Israel.